WO2006013472A3 - Novel anti-igf-ir antibodies and uses thereof - Google Patents

Novel anti-igf-ir antibodies and uses thereof Download PDF

Info

Publication number
WO2006013472A3
WO2006013472A3 PCT/IB2005/002619 IB2005002619W WO2006013472A3 WO 2006013472 A3 WO2006013472 A3 WO 2006013472A3 IB 2005002619 W IB2005002619 W IB 2005002619W WO 2006013472 A3 WO2006013472 A3 WO 2006013472A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
igf
overexpression
receptor
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002619
Other languages
French (fr)
Other versions
WO2006013472A2 (en
Inventor
Liliane Goetsch
Nathalie Corvaia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34950307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006013472(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP05780625.9A priority Critical patent/EP1771481B1/en
Priority to US11/658,739 priority patent/US7854930B2/en
Priority to KR1020077004904A priority patent/KR101220635B1/en
Priority to MX2007001109A priority patent/MX2007001109A/en
Priority to JP2007523178A priority patent/JP5016487B2/en
Priority to CN2005800251969A priority patent/CN101014625B/en
Priority to NZ552821A priority patent/NZ552821A/en
Priority to CA002575348A priority patent/CA2575348A1/en
Priority to AU2005268505A priority patent/AU2005268505B2/en
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to BRPI0513890-6A priority patent/BRPI0513890A/en
Priority to HK07110853.8A priority patent/HK1102600B/en
Publication of WO2006013472A2 publication Critical patent/WO2006013472A2/en
Publication of WO2006013472A3 publication Critical patent/WO2006013472A3/en
Priority to IL181025A priority patent/IL181025A/en
Anticipated expiration legal-status Critical
Priority to NO20071093A priority patent/NO20071093L/en
Priority to US12/973,480 priority patent/US8124079B2/en
Priority to US13/352,976 priority patent/US8420085B2/en
Priority to IL229778A priority patent/IL229778A0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or anti-VEGF antibodies and/or antibodies directed against other growth factors involved in tumor progression or metastasis and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
PCT/IB2005/002619 2004-07-29 2005-07-27 Novel anti-igf-ir antibodies and uses thereof Ceased WO2006013472A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
HK07110853.8A HK1102600B (en) 2004-07-29 2005-07-27 Novel anti-igf-ir antibodies and uses thereof
BRPI0513890-6A BRPI0513890A (en) 2004-07-29 2005-07-27 antibody, murine hybridoma, composition, use thereof, and in vitro diagnostic method of disease
KR1020077004904A KR101220635B1 (en) 2004-07-29 2005-07-27 Novel anti-ｉｇｆ-ｉｒ antibodies and uses thereof
MX2007001109A MX2007001109A (en) 2004-07-29 2005-07-27 Novel anti-igf-ir antibodies and uses thereof.
JP2007523178A JP5016487B2 (en) 2004-07-29 2005-07-27 Novel anti-IGF-IR antibody and use thereof
CN2005800251969A CN101014625B (en) 2004-07-29 2005-07-27 Novel anti-IGF-IR antibodies and uses thereof
NZ552821A NZ552821A (en) 2004-07-29 2005-07-27 Novel anti-IGF-IR antibodies and uses thereof
CA002575348A CA2575348A1 (en) 2004-07-29 2005-07-27 Novel anti-igf-ir antibodies and uses thereof
AU2005268505A AU2005268505B2 (en) 2004-07-29 2005-07-27 Novel anti-IGF-IR antibodies and uses thereof
EP05780625.9A EP1771481B1 (en) 2004-07-29 2005-07-27 Novel anti-igf-ir antibodies and uses thereof
US11/658,739 US7854930B2 (en) 2004-07-29 2005-07-27 Anti-igf-ir antibodies and uses thereof
IL181025A IL181025A (en) 2004-07-29 2007-01-29 Anti-igf-ir antibodies, uses thereof and compositions comprising same
NO20071093A NO20071093L (en) 2004-07-29 2007-02-27 Novel anti-IGF-IR antibodies and their use
US12/973,480 US8124079B2 (en) 2004-07-29 2010-12-20 Anti-IGF-IR antibodies and uses thereof
US13/352,976 US8420085B2 (en) 2004-07-29 2012-01-18 Anti-IGF-IR antibodies and uses thereof
IL229778A IL229778A0 (en) 2004-07-29 2013-12-03 Novel anti-igf-ir antibodies, uses thereof and compositions comprising same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59193204P 2004-07-29 2004-07-29
FR0408379 2004-07-29
US60/591,932 2004-07-29
FR0408379A FR2873699B1 (en) 2004-07-29 2004-07-29 NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/658,739 A-371-Of-International US7854930B2 (en) 2004-07-29 2005-07-27 Anti-igf-ir antibodies and uses thereof
US12/973,480 Division US8124079B2 (en) 2004-07-29 2010-12-20 Anti-IGF-IR antibodies and uses thereof

Publications (2)

Publication Number Publication Date
WO2006013472A2 WO2006013472A2 (en) 2006-02-09
WO2006013472A3 true WO2006013472A3 (en) 2006-05-11

Family

ID=34950307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002619 Ceased WO2006013472A2 (en) 2004-07-29 2005-07-27 Novel anti-igf-ir antibodies and uses thereof

Country Status (22)

Country Link
US (3) US7854930B2 (en)
EP (4) EP2365006A3 (en)
JP (3) JP5016487B2 (en)
KR (1) KR101220635B1 (en)
CN (2) CN101014625B (en)
AR (1) AR050036A1 (en)
AU (1) AU2005268505B2 (en)
BR (1) BRPI0513890A (en)
CA (1) CA2575348A1 (en)
CO (1) CO5700152A1 (en)
FR (1) FR2873699B1 (en)
GT (1) GT200500205A (en)
IL (2) IL181025A (en)
MX (1) MX2007001109A (en)
NO (1) NO20071093L (en)
NZ (2) NZ552821A (en)
PA (1) PA8640601A1 (en)
RU (2) RU2406729C2 (en)
SV (1) SV2006002182A (en)
TW (1) TWI432451B (en)
WO (1) WO2006013472A2 (en)
ZA (1) ZA200700593B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553485B2 (en) 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP2365001A3 (en) 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
FR2873699B1 (en) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF
EP2281841A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarkers for pre-selection of patients for anti-IGF1R therapy
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
CA2678008C (en) 2005-06-17 2013-07-30 Imclone Systems Incorporated Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies
FR2888850B1 (en) * 2005-07-22 2013-01-11 Pf Medicament NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
AU2007212447B2 (en) 2006-02-03 2013-02-21 Imclone Llc IGF-IR antagonists as adjuvants for treatment of prostate cancer
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
EA200900991A1 (en) * 2007-02-14 2010-02-26 Глаксо Груп Лимитед NEW ANTIBODIES AGAINST IGF-1R
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
WO2009080278A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Stability testing of antibodies
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
US8444982B2 (en) * 2009-12-04 2013-05-21 The University Of Hong Kong Anti-IGF-IR antibodies and uses thereof
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
ES2545411T5 (en) 2010-06-07 2024-04-05 Amgen Inc drug delivery device
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
WO2012135315A1 (en) 2011-03-31 2012-10-04 Amgen Inc. Vial adapter and system
LT2699293T (en) 2011-04-20 2019-04-25 Amgen Inc. Autoinjector apparatus
EP3045187B1 (en) 2011-10-14 2019-04-10 Amgen Inc. Injector and method of assembly
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
EP2631653A1 (en) 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
EP2863947B1 (en) * 2012-06-21 2018-03-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind igf1r
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CN102830223A (en) * 2012-08-14 2012-12-19 四川汇宇制药有限公司 Screening method for drugs used for treating neoplastic diseases in mammals
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
JP2015535464A (en) 2012-11-21 2015-12-14 アムジエン・インコーポレーテツド Drug delivery device
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
TWI592183B (en) 2013-03-15 2017-07-21 安美基公司 Automatic injector device with adjustable body contour
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
ES2853748T3 (en) 2013-03-22 2021-09-17 Amgen Inc Injector and mounting method
DK3043810T3 (en) 2013-09-09 2020-01-27 Canimguide Therapeutics Ab Immune system modulators
MX2016005315A (en) 2013-10-24 2016-08-11 Amgen Inc Drug delivery system with temperature-sensitive control.
EP3060275B1 (en) 2013-10-24 2019-07-03 Amgen Inc. Injector and method of assembly
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
CN106459204B (en) * 2014-04-25 2021-02-02 皮埃尔法布雷医药公司 IGF-1R antibody and its use as a targeting carrier for the treatment of cancer
SG11201609219QA (en) 2014-05-07 2016-12-29 Amgen Inc Autoinjector with shock reducing elements
US20170103186A1 (en) 2014-06-03 2017-04-13 Amgen Inc. Systems and methods for supporting patient use of a drug delivery device
ES3056224T3 (en) 2014-10-14 2026-02-19 Amgen Inc Drug injection device with visual and audible indicators
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
US10583245B2 (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (en) 2015-02-27 2022-04-12 Amgen Inc Drug delivery device having a needle guard mechanism with an adjustable threshold resistance to movement of the needle guard
WO2016144650A1 (en) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
JP7082568B2 (en) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド Automatic syringe with signal transduction cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
JP7014724B2 (en) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド Tandem-type Fab immunoglobulin and its use
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (en) 2016-05-13 2019-02-21 Amgen Inc Vial sleeve assembly.
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
ES3066292T3 (en) 2016-06-03 2026-05-12 Amgen Inc Impact testing apparatuses and methods for drug delivery devices
EP3478342B1 (en) 2016-07-01 2025-03-12 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127B1 (en) 2016-10-25 2026-04-08 Amgen Inc. On-body injector
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
MX2019009755A (en) 2017-02-17 2019-10-07 Amgen Inc Insertion mechanism for drug delivery device.
AU2018220538B2 (en) 2017-02-17 2023-12-14 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
KR102627069B1 (en) 2017-03-07 2024-01-18 암겐 인코포레이티드 Needle insertion due to overpressure
SG11201908062QA (en) 2017-03-09 2019-09-27 Amgen Inc Insertion mechanism for drug delivery device
MX2019011416A (en) 2017-03-28 2019-11-01 Amgen Inc SYSTEM AND METHOD FOR ASSEMBLY OF SYRINGE AND PLUNGER STEM.
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
MA49447A (en) 2017-06-22 2020-04-29 Amgen Inc REDUCTION OF IMPACTS / SHOCKS OF ACTIVATION OF A DEVICE
JP7475860B2 (en) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド Electronic drug delivery device including a cap activated by a switch assembly - Patents.com
JP7408398B2 (en) 2017-07-14 2024-01-05 アムジエン・インコーポレーテツド Needle insertion and retraction system with dual torsion spring system
JP7649105B2 (en) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド Gas-permeable sealing member for drug containers and method of assembly - Patents.com
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
EP3658206A1 (en) 2017-07-25 2020-06-03 Amgen Inc. Drug delivery device with container access system and related method of assembly
US12318593B2 (en) 2017-08-09 2025-06-03 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567B1 (en) 2017-08-18 2026-02-18 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
MA50348A (en) 2017-10-09 2020-08-19 Amgen Inc DRUG ADMINISTRATION DEVICE INCLUDING A TRAINING ASSEMBLY AND ASSOCIATED ASSEMBLY PROCEDURE
ES3069718T3 (en) 2017-11-03 2026-06-10 Amgen Inc System and approaches for sterilizing a drug delivery device
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
MA50569A (en) 2017-11-06 2020-09-16 Amgen Inc FILLING-FINISHING UNITS AND ASSOCIATED PROCESSES
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Pistons for drug delivery devices
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
JP7747438B2 (en) 2017-11-16 2025-10-01 アムジエン・インコーポレーテツド Autoinjector with stall and end-point detection
BR112020011875A2 (en) 2017-12-14 2020-11-24 Abl Bio Inc. bispecific antibody to a-syn / igf1r and use thereof
CN112074541A (en) 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins prepared therefrom
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
CN112469454B (en) 2018-07-24 2024-01-26 安进公司 Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MA53320A (en) 2018-07-31 2021-11-03 Amgen Inc FLUID PATH ASSEMBLY FOR DRUG DELIVERY DEVICE
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
US12042642B2 (en) 2018-09-28 2024-07-23 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
JP7547325B2 (en) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド Drug delivery device having a dosage indicator - Patents.com
MA53913A (en) 2018-10-15 2022-01-19 Amgen Inc METHOD OF ASSEMBLING DRUG DELIVERY DEVICE PLATFORM
JP7719714B2 (en) 2018-10-15 2025-08-06 アムジエン・インコーポレーテツド Drug delivery device with damping mechanism
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (en) 2018-11-01 2024-02-11 美商安進公司 Drug delivery devices with partial needle retraction and methods for operating the same
MA54057A (en) 2018-11-01 2022-02-09 Amgen Inc DRUG DELIVERY ELEMENT PARTIAL RETRACTION DRUG DELIVERY DEVICES
EP3958934B1 (en) 2019-04-24 2025-04-09 Amgen Inc. Syringe sterilization verification assemblies and methods
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
JP2022545835A (en) 2019-08-28 2022-10-31 ホライゾン セラピューティクス アイルランド デジグネイテッド アクティビティ カンパニー How to treat thyroid eye disease
AU2020358898B2 (en) * 2019-10-01 2025-10-16 Epsilogen Ltd Hybrid antibody
WO2022086620A1 (en) * 2020-10-20 2022-04-28 The Methodist Hospital System Psma-targeted immunotherapies for cancers
US20240052029A1 (en) * 2021-01-12 2024-02-15 Bioheng Therapeutics Limited Ror1-targeting antibody and use thereof
BR112023024278A2 (en) 2021-05-21 2024-01-30 Amgen Inc METHOD OF OPTIMIZING A FILLING RECIPE FOR A DRUG CONTAINER
AU2024244149A1 (en) * 2023-04-04 2025-08-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-igf1r antibodies and uses thereof
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
WO2003059951A2 (en) * 2002-01-18 2003-07-24 Pierre Fabre Medicament Novel anti-igf-ir antibodies and uses thereof
WO2003100008A2 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
WO2003106621A2 (en) * 2002-06-14 2003-12-24 Immunogen, Inc. Anti-igf-i receptor antibody

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (en) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
AU2001241710B2 (en) * 2000-02-25 2005-07-21 The Regents Of The University Of California Membrane estrogen receptor-directed therapy in breast cancer
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
GB0219524D0 (en) * 2002-08-21 2002-10-02 Queen Mary & Westfield College Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
CA2519113C (en) * 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
CN1835975B (en) * 2003-08-13 2012-11-21 辉瑞产品公司 Modified human IGF-1R antibodies
FR2873699B1 (en) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF
FR2888850B1 (en) * 2005-07-22 2013-01-11 Pf Medicament NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS
FR2907341B1 (en) * 2006-10-18 2012-08-17 Pf Medicament USE OF ANTI-CD151 ANTIBODY FOR THE TREATMENT OF CANCER

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
WO2003059951A2 (en) * 2002-01-18 2003-07-24 Pierre Fabre Medicament Novel anti-igf-ir antibodies and uses thereof
WO2003100008A2 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
WO2003106621A2 (en) * 2002-06-14 2003-12-24 Immunogen, Inc. Anti-igf-i receptor antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI S-L ET AL: "SINGLE-CHAIN ANTIBODIES AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR I RECEPTOR: EXPRESSION, PURIFICATION AND EFFECT ON TUMOR GROWTH", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 49, no. 4/5, July 2000 (2000-07-01), pages 243 - 252, XP001113064, ISSN: 0340-7004 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression

Also Published As

Publication number Publication date
EP2365005A3 (en) 2011-10-26
SV2006002182A (en) 2006-10-04
WO2006013472A2 (en) 2006-02-09
FR2873699A1 (en) 2006-02-03
JP2012153692A (en) 2012-08-16
CN101014625B (en) 2013-07-03
EP2380912A1 (en) 2011-10-26
NO20071093L (en) 2007-02-27
US8420085B2 (en) 2013-04-16
CN101014625A (en) 2007-08-08
US20120183559A1 (en) 2012-07-19
US8124079B2 (en) 2012-02-28
ZA200700593B (en) 2008-05-28
FR2873699B1 (en) 2009-08-21
EP1771481B1 (en) 2014-05-14
HK1102600A1 (en) 2007-11-30
KR20070057814A (en) 2007-06-07
RU2007107589A (en) 2008-09-10
RU2009138977A (en) 2011-04-27
IL229778A0 (en) 2014-01-30
CN103951752A (en) 2014-07-30
TWI432451B (en) 2014-04-01
AR050036A1 (en) 2006-09-20
JP5016487B2 (en) 2012-09-05
RU2406729C2 (en) 2010-12-20
EP2365006A2 (en) 2011-09-14
GT200500205A (en) 2006-03-02
US7854930B2 (en) 2010-12-21
US20110091479A1 (en) 2011-04-21
EP1771481A2 (en) 2007-04-11
BRPI0513890A (en) 2008-05-20
AU2005268505B2 (en) 2011-11-17
EP2365006A3 (en) 2011-10-19
IL181025A0 (en) 2007-07-04
NZ552821A (en) 2009-10-30
IL181025A (en) 2013-12-31
CO5700152A1 (en) 2006-11-30
EP2365005A2 (en) 2011-09-14
AU2005268505A1 (en) 2006-02-09
US20090214525A1 (en) 2009-08-27
CA2575348A1 (en) 2006-02-09
PA8640601A1 (en) 2006-08-03
JP2008515773A (en) 2008-05-15
MX2007001109A (en) 2007-04-19
TW200628490A (en) 2006-08-16
NZ569718A (en) 2010-03-26
KR101220635B1 (en) 2013-01-11
JP2014193862A (en) 2014-10-09

Similar Documents

Publication Publication Date Title
EP2365005A3 (en) Novel anti-IGF-IR antibodies and uses thereof
WO2005058967A8 (en) Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
WO2003059951A8 (en) Novel anti-igf-ir antibodies and uses thereof
TN2012000558A1 (en) Novel anti-cmet antibody
IL147271A (en) Isolated peptide ligands that bind her2
JP2021527706A5 (en)
WO2007126876A3 (en) Anti-igf-ir antibodies and uses thereof
WO2007012614A3 (en) Novel anti-igf-ir antibodies and uses thereof
WO2005099756A3 (en) ErbB ANTAGONISTS FOR PAIN THERAPY
NZ592151A (en) Anti-igf antibodies
GEP20135826B (en) Novel antibodies used to treat cancer
UA101603C2 (en) Normal;heading 1;heading 2;heading 3;HUMANIZED ANTI-FACTOR D ANTIBODIES AND USE THEREOF
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
WO2010022736A3 (en) Recombinant anti-epidermal growth factor receptor antibody compositions
WO2009025867A3 (en) Compositions of humanized notch fusion proteins and methods of treatment
GEP20115324B (en) Tweak binding antibodies
WO2006087637A3 (en) Anti her2/neu antibody
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
EP2431050A8 (en) Methods of treating cancer using IL-21 and monoclonal antibody therapy
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2005000207A3 (en) Pcdgf receptor antibodies and methods of use thereof
TN2012000151A1 (en) Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer
AU2016219676A1 (en) Anti-activin A antibodies and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005780625

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007/00593

Country of ref document: ZA

Ref document number: 200700593

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005268505

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580025196.9

Country of ref document: CN

Ref document number: 552821

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/001109

Country of ref document: MX

Ref document number: 2575348

Country of ref document: CA

Ref document number: 2007523178

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11658739

Country of ref document: US

Ref document number: 181025

Country of ref document: IL

Ref document number: 743/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005268505

Country of ref document: AU

Date of ref document: 20050727

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005268505

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007107589

Country of ref document: RU

Ref document number: 1020077004904

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005780625

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0513890

Country of ref document: BR